Puma Biotechnology, Inc. (PBYI)
10.22
+0.39
(+3.97%)
USD |
NASDAQ |
Oct 19, 16:00
10.22
0.00 (0.00%)
After-Hours: 20:00
Puma Biotechnology Gross Profit Margin (Quarterly) : 77.92% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 77.92% |
| March 31, 2026 | 76.74% |
| December 31, 2025 | 69.35% |
| September 30, 2025 | 77.65% |
| June 30, 2025 | 76.54% |
| March 31, 2025 | 77.06% |
| December 31, 2024 | 76.44% |
| September 30, 2024 | 63.87% |
| June 30, 2024 | 77.36% |
| March 31, 2024 | 75.49% |
| December 31, 2023 | 66.30% |
| September 30, 2023 | 76.33% |
| June 30, 2023 | 78.27% |
| March 31, 2023 | 74.95% |
| December 31, 2022 | 74.36% |
| September 30, 2022 | 78.12% |
| June 30, 2022 | 74.94% |
| March 31, 2022 | 76.29% |
| Date | Value |
|---|---|
| December 31, 2021 | 78.52% |
| September 30, 2021 | 77.77% |
| June 30, 2021 | 77.58% |
| March 31, 2021 | 69.89% |
| December 31, 2020 | 79.28% |
| September 30, 2020 | 80.41% |
| June 30, 2020 | 86.66% |
| March 31, 2020 | 82.28% |
| December 31, 2019 | 83.94% |
| September 30, 2019 | 83.37% |
| June 30, 2019 | 82.72% |
| March 31, 2019 | 91.94% |
| December 31, 2018 | 85.51% |
| September 30, 2018 | 85.55% |
| June 30, 2018 | 82.60% |
| March 31, 2018 | 90.40% |
| December 31, 2017 | 81.02% |
| September 30, 2017 | 74.89% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Anika Therapeutics, Inc. | 65.15% |
| Arcutis Biotherapeutics, Inc. | 91.58% |
| Olema Pharmaceuticals, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 21.64% |
| Return on Assets | 13.35% |
| Return on Invested Capital | 17.65% |
| Profit Margin (Quarterly) | 14.49% |
| Operating Margin (Quarterly) | 13.42% |
| Return on Net Operating Assets | 28.59% |